Fund detail
Dodge & Cox
large-active, value, lo
Quarters
52
2023-09-30
$148.40B
Positions
192
2026-03-31
2025-12-31
2025-09-30
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30
2014-06-30
2014-03-31
2013-12-31
2013-09-30
2013-06-30
Price is the latest implied close from the selected quarter's 13F (value ÷ shares). Est. Cost is a running average that assumes each quarter's trades cleared near the midpoint of consecutive 13F closes (or yfinance VWAP when available). Most accurate for slow accumulators, least accurate for activists who build positions in a few days.
| # | Issuer | Value ↓ | Weight | Shares | Share Δ | Share Δ % | Prev Weight | First Held | Price | Est. Cost | Unrealized % | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | VF Corp. VFC | $567.5M | 0.38% | 32,115,750 | +32,115,750 | 2013-06-30 | $18 | ~$44 | -59.60% | |||
| 2 | Baxter International, Inc. BAX | $371.7M | 0.25% | 9,848,441 | +9,848,441 | 2013-06-30 | $38 | ~$51 | -25.93% | |||
| 3 | Avantor, Inc. AVTR | $280.2M | 0.19% | 13,291,904 | +13,291,904 | 2023-09-30 | $21 | ~$21 | +0.00% | |||
| 4 | Neurocrine Biosciences, Inc. NBIX | $24.0M | 0.02% | 213,602 | +213,602 | 2023-09-30 | $112 | ~$112 | +0.00% |